New treatments for allergen immunotherapy (Q27016089)

language of work or name

1 reference

2014

1 reference

The World Allergy Organization Journal

published in

1 reference

volume

7

1 reference

issue

1

1 reference

page(s)

23

1 reference

https://scigraph.springernature.com/pub.10.1186/1939-4551-7-23

exact match

0 references

cites work

Sublingual immunotherapy: World Allergy Organization position paper 2013 update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174392

Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174392

Effector and central memory T helper 2 cells respond differently to peptide immunotherapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174392

Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174392

IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174392

Severe chronic allergic (and related) diseases: a uniform approach--a MeDALL--GA2LEN--ARIA position paper

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174392

Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174392

Systematic reviews of sublingual immunotherapy (SLIT).

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174392

Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174392

Oral tolerance to food-induced systemic anaphylaxis mediated by the C-type lectin SIGNR1

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174392

Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174392

Modular antigen-translocation as a novel vaccine strategy for allergen-specific immunotherapy.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174392

Engineering of major house dust mite allergens Der p 1 and Der p 2 for allergen-specific immunotherapy.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174392

House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174392

Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174392

Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174392

A recombinant allergen chimer as novel mucosal vaccine candidate for prevention of multi-sensitivities

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174392

Vaccination with genetically engineered allergens prevents progression of allergic disease.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174392

Bypassing IgE and targeting T cells for specific immunotherapy of allergy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174392

A novel human immunoglobulin Fc gamma Fc epsilon bifunctional fusion protein inhibits Fc epsilon RI-mediated degranulation

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174392

Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4174392

A major allergen gene-fusion protein for potential usage in allergen-specific immunotherapy.

31 May 2018

1 reference

https://api.crossref.org/works/10.1186%2F1939-4551-7-23

Prevention of allergy by a recombinant multi-allergen vaccine with reduced IgE binding and preserved T cell epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1939-4551-7-23

Analysis of epitope-specific immune responses induced by vaccination with structurally folded and unfolded recombinant Bet v 1 allergen derivatives in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1939-4551-7-23

Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1939-4551-7-23

Prolonged antigen-exposure with carbohydrate particle based vaccination prevents allergic immune responses in sensitized mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1939-4551-7-23

A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1939-4551-7-23

Tolerance induction after specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1939-4551-7-23

A chimeric human-cat fusion protein blocks cat-induced allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1939-4551-7-23

Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1939-4551-7-23

Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1939-4551-7-23

Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1939-4551-7-23

Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1939-4551-7-23

Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1939-4551-7-23

Treatment of cat allergy with T-cell reactive peptides

21 January 2018

1 reference

12 December 2020

Allergen-specific immunotherapy with recombinant grass pollen allergens

1 reference

12 December 2020

Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding

1 reference

12 December 2020

Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis

1 reference

12 December 2020

Toll-like receptor 4 ligation enforces tolerogenic properties of oral mucosal Langerhans cells

1 reference

12 December 2020

Immunotherapy with peptides

1 reference

12 December 2020

Recombinant allergens for specific immunotherapy

1 reference

12 December 2020

Induction and maintenance of allergen-specific FOXP3+ Treg cells in human tonsils as potential first-line organs of oral tolerance

1 reference

12 December 2020

Triggering of specific Toll-like receptors and proinflammatory cytokines breaks allergen-specific T-cell tolerance in human tonsils and peripheral blood

1 reference

12 December 2020

Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial

1 reference

12 December 2020

Identifiers

DOI

10.1186/1939-4551-7-23

1 reference

Dimensions Publication ID

2629031

1032017176

0 references

2629031

1 reference

1 reference

1 reference